{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:18:54Z","timestamp":1794291534949,"version":"4.9.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate the long-term safety and efficacy of bremelanotide as treatment for hypoactive sexual desire disorder in premenopausal women.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>Women who completed the 24-week double-blind core phase of RECONNECT, composed of two parallel phase 3 trials (301 and 302) examining the safety and efficacy of bremelanotide compared with placebo in premenopausal women with hypoactive sexual desire disorder, could enroll in the 52-week open-label extension, provided they had not experienced serious adverse events during the core phase. Efficacy was assessed using the coprimary endpoints from the core phase, and all adverse events were collected during the open-label extension. All statistical analyses were descriptive.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>The study 301 open-label extension began on July 17, 2015, and concluded on July 13, 2017; the study 302 open-label extension began on October 5, 2015, and concluded on June 29, 2017. Of the 856 eligible patients who completed the core phase, 684 elected to participate in the open-label extension, and 272 completed it. The most common treatment-emergent adverse events considered related to study drug were nausea (40.4%), flushing (20.6%), and headache (12.0%), and the only severe treatment-emergent adverse event experienced by more than one participant in both studies was nausea during the open-label extension. The change in Female Sexual Function Index\u2013desire domain score and Female Sexual Distress Scale\u2013Desire\/Arousal\/Orgasm item 13 from baseline to end of the open-label extension ranged from 1.25 to 1.30 and \u22121.4 to \u22121.7, respectively, for patients who received bremelanotide during the core phase, and 0.70\u20130.77 and \u22120.9, respectively, for patients who received placebo during the core phase.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>During the 52-week open-label extension of RECONNECT, no new safety signals were observed, and premenopausal women treated with bremelanotide exhibited sustained improvements in hypoactive sexual desire disorder symptoms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n            <jats:p>\n                                 ClinicalTrials.gov, NCT02333071 (study 301) and NCT02338960 (study 302).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>FUNDING SOURCE:<\/jats:title>\n            <jats:p>Palatin Technologies, Inc., and AMAG Pharmaceuticals, Inc.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000003514","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T11:39:00Z","timestamp":1570707540000},"page":"909-917","source":"Crossref","is-referenced-by-count":41,"title":["Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder"],"prefix":"10.1097","volume":"134","author":[{"given":"James A.","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl A.","family":"Kingsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Portman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Krop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johna","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita H.","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230925","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/AOG.0b013e3181898cdb","article-title":"Sexual problems and distress in United States women: prevalence and correlates","volume":"112","author":"Shifren","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R3-20230925","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.sxmr.2015.11.009","article-title":"Hypoactive sexual desire disorder: a review of epidemiology, biopsychology, diagnosis, and treatment","volume":"4","author":"Parish","year":"2016","journal-title":"Sex Med Rev"},{"key":"R4-20230925","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mayocp.2016.09.018","article-title":"Hypoactive sexual desire disorder: International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review","volume":"92","author":"Goldstein","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"R5-20230925","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jsxm.2016.09.020","article-title":"Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions\u2014part II","volume":"13","author":"Parish","year":"2016","journal-title":"J Sex Med"},{"key":"R6-20230925","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/1468199031000061308","article-title":"Biopsychosocial models of women's sexual response: applications to management of \u201cdesire disorders.\u201d","volume":"18","author":"Basson","year":"2003","journal-title":"Sex Relation Ther"},{"key":"R7-20230925","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.neuroscience.2008.09.044","article-title":"Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study","volume":"158","author":"Arnow","year":"2009","journal-title":"Neuroscience"},{"key":"R8-20230925","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1111\/j.1743-6109.2011.02376.x","article-title":"Neural bases of hypoactive sexual desire disorder in women: an event-related FMRI study","volume":"8","author":"Bianchi-Demicheli","year":"2011","journal-title":"J Sex Med"},{"key":"R9-20230925","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/jsm.12410","article-title":"Reduced gray matter volume and increased white matter fractional anisotropy in women with hypoactive sexual desire disorder","volume":"11","author":"Bloemers","year":"2014","journal-title":"J Sex Med"},{"key":"R10-20230925","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.fertnstert.2013.05.041","article-title":"Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: a cross-sectional pilot study","volume":"100","author":"Woodard","year":"2013","journal-title":"Fertil Steril"},{"key":"R11-20230925","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/GME.0000000000000134","article-title":"Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial","volume":"21","author":"Simon","year":"2014","journal-title":"Menopause"},{"key":"R12-20230925","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1743-6109.2011.02595.x","article-title":"Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study","volume":"9","author":"Thorp","year":"2012","journal-title":"J Sex Med"},{"key":"R13-20230925","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1743-6109.2011.02626.x","article-title":"Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study","volume":"9","author":"Derogatis","year":"2012","journal-title":"J Sex Med"},{"key":"R14-20230925","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1111\/j.1743-6109.2011.02458.x","article-title":"Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder (HSDD): results from a randomized withdrawal trial","volume":"8","author":"Goldfischer","year":"2011","journal-title":"J Sex Med"},{"key":"R15-20230925","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/jsm.12189","article-title":"Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial","volume":"10","author":"Katz","year":"2013","journal-title":"J Sex Med"},{"key":"R16-20230925","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2217\/whe-2016-0018","article-title":"Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial","volume":"12","author":"Clayton","year":"2016","journal-title":"Womens Health (Lond)"},{"key":"R19-20230925","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1749-6632.2003.tb03167.x","article-title":"PT-141: a melanocortin agonist for the treatment of sexual dysfunction","volume":"994","author":"Molinoff","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"suppl 4","key":"R20-20230925","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1743-6109.2007.00610.x","article-title":"Bremelanotide: an overview of preclinical CNS effects on female sexual function","volume":"4","author":"Pfaus","year":"2007","journal-title":"J Sex Med"},{"key":"R21-20230925","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-015-0288-1","article-title":"The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder","volume":"29","author":"Kingsberg","year":"2015","journal-title":"CNS Drugs"},{"key":"R22-20230925","doi-asserted-by":"crossref","first-page":"10201","DOI":"10.1073\/pnas.0400491101","article-title":"Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist","volume":"101","author":"Pfaus","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"R23-20230925","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/AOG.0000000000003500","article-title":"Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials","volume":"134","author":"Kingsberg","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R24-20230925","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jsxm.2019.05.012","article-title":"Responder analyses from a phase 2b dose-ranging study of bremelanotide","volume":"16","author":"Althof","year":"2019","journal-title":"J Sex Med"},{"key":"R25-20230925","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/009262300278597","article-title":"The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function","volume":"26","author":"Rosen","year":"2000","journal-title":"J Sex Marital Ther"},{"key":"R26-20230925","article-title":"U.S. Food and Drug Administration. Summary review for regulatory action"},{"key":"R27-20230925"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T22:00:15Z","timestamp":1695679215000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003514","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}